ABSI
Absci Corporation
$5.10
+0.01
(+0.20%)
Mkt Cap
795.12M
Volume
2,241,735
52W Range
2.24-6.72
Sector
Healthcare
Beta
2.38
EPS (TTM)
-0.83
P/E Ratio
-4.14
Revenue (TTM)
1.84M
Rev Growth (5Y)
-10.1%
EPS Growth (5Y)
N/A
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Net Income | (115.18M) | (103.11M) | (110.57M) | (104.90M) | (100.96M) | (14.35M) | (6.58M) |
| EPS | -0.84 | -0.94 | -1.20 | -1.15 | -1.11 | -0.54 | -0.07 |
| Free Cash Flow | (94.03M) | (72.81M) | (65.50M) | (97.51M) | (98.64M) | (13.15M) | (7.13M) |
| FCF / Share | -0.69 | -0.66 | -0.71 | -1.07 | -1.06 | -0.14 | -0.08 |
| Operating CF | (92.92M) | (72.40M) | (64.64M) | (81.34M) | (60.60M) | (10.97M) | (6.03M) |
| Total Assets | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M | 88.57M | 19.47M |
| Total Debt | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M | 14.50M | 6.02M |
| Cash & Equiv | 20.02M | 41.21M | 72.36M | 59.95M | 252.57M | 69.87M | 13.09M |
| Book Value | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M | 67.00M | (41.16M) |
| Return on Equity | -0.61 | -0.58 | -0.63 | -0.38 | -0.28 | -0.21 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215,000 | 650,000 | 378,000 | 593,000 | 1.18M | 665,000 | 1.70M | 1.27M | 898,000 | 338,000 | 744,000 | 3.37M |
| Net Income | (29.60M) | (29.56M) | (28.71M) | (30.57M) | (26.35M) | (28.98M) | (27.40M) | (24.75M) | (21.98M) | (23.55M) | (21.99M) | (41.67M) |
| EPS | -0.19 | -0.20 | -0.20 | -0.24 | -0.21 | -0.25 | -0.24 | -0.22 | -0.22 | -0.25 | -0.24 | -0.45 |
| Free Cash Flow | (26.34M) | (29.08M) | (25.99M) | (17.10M) | (21.86M) | (16.99M) | (20.78M) | (17.18M) | (17.86M) | (14.94M) | (10.67M) | (19.49M) |
| FCF / Share | -0.17 | -0.19 | -0.18 | -0.13 | -0.18 | -0.15 | -0.18 | -0.15 | -0.18 | -0.16 | -0.12 | -0.21 |
| Operating CF | (26.31M) | (29.18M) | (25.03M) | (16.87M) | (21.84M) | (16.96M) | (20.73M) | (16.84M) | (17.86M) | (14.92M) | (10.36M) | (19.23M) |
| Total Assets | 195.59M | 216.30M | 244.99M | 209.89M | 232.45M | 213.61M | 235.23M | 255.53M | 274.90M | 217.30M | 236.34M | 254.15M |
| Total Debt | 4.42M | 5.30M | 6.22M | 7.41M | 8.92M | 10.11M | 11.99M | 13.33M | 14.24M | 15.88M | 17.75M | 19.47M |
| Cash & Equiv | 8.63M | 20.02M | 9.48M | 38.02M | 46.99M | 41.21M | 38.20M | 42.94M | 58.83M | 72.36M | 69.73M | 61.05M |
| Book Value | 171.97M | 189.45M | 210.34M | 173.37M | 198.80M | 179.13M | 201.34M | 221.49M | 240.11M | 176.18M | 196.42M | 215.40M |
| Return on Equity | -0.17 | -0.16 | -0.14 | -0.18 | -0.13 | -0.16 | -0.14 | -0.11 | -0.09 | -0.13 | -0.11 | -0.19 |
ABSI News
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis
Absci Q4 Earnings Call Highlights